509. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323–1328.
510. Stinton C. et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis //American Journal of Psychiatry. – 2015. – Т. 172. – №. 8. C. 731-742
511. Wang H, Yu J, Tang S, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Journal of Neurology, Neurosurgery & Psychiatry 2015;86:135-143.
512. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17(3):1611–1624.
513. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews 2012, Issue 3.
514. Wild R, Pettit TACL, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2003, Issue 3.
515. Dou KX, Tan MS, Tan CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.
516. Brennan L., Pantelyat A., Duda J.E. et al. Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. Mov Disord Clin Pract. 2015;3(2):161–167.
517. Fischer C., Bozanovic R., Atkins J., Rourke S. Treatment of Delusions in Dementia with Lewy Bodies – Response to Pharmacotherapy. Dement Geriatr Cogn Disord 2007;23:307-311.
518. Schneider L.S., Dagerman K.S., Insel P. Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials. JAMA. 2005;294(15):1934–1943.
519. Yunusa I., Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019;2(3):e190828. Published 2019 Mar 1.
520. Ma Huia; Huang Yinglina; Cong Zhengtua, Wang, Yuana, Jiang, Wenhaid, Gao Shuhed, Zhun Ganga The Efficacy and Safety of Atypical Antipsychotics for the Treatment of Dementia: A Meta-Analysis of Randomized Placebo-Controlled Trials
521. Aarsland D., Perry R., Larsen J.P., McKeith I. G., et al. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
522. Akiko Kobayashi, Chiaki Kawanishi, Takehiko Matsumura, Daiji Kato, Ryoko Furukawa, Ikuko Kishida, Yoshio Hirayasu. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report. Progress in Neuro- Psychopharmacology and Biological Psychiatry, Volume 30, Issue 6, 2006, Pages 1170-1172.
523. Piggott M. A. et al. Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease. Biological Psychiatry, Volume 44, Issue 8, 765 – 774
524. Sechi G., Agnetti V., Masuri R., Deiana A. G. et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies, Progress in Neuro- Psychopharmacology and Biological Psychiatry, Volume 24, Issue 6, 2000, Pages 1043-1051.
525. Hubert H. Fernandez, Martha E. Trieschmann, Monica A. Burke, and Joseph H. Friedman Quetiapine for Psychosis in Parkinson's Disease Versus Dementia With Lewy Bodies. J Clin Psychiatry 2002;63(6):513-515.
526. Kurlan R. et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism //Neurology. – 2007. – Т. 68. – №. 17. C. 1356-1363.
527. Bhamra M, Rajkumar AP, Ffytche DH, et al. Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies. Case Reports 2018;2018:bcr-2018-224710.
528. Hitoshi Takahashi, Keizo Yoshida, Takio Sugita, Hisashi Higuchi, Tetsuo Shimizu, Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 27, Issue 3, 2003, Pages 549-553,
529. Andrius Baskys, MD, PhD. Lewy Body Dementia: The Litmus Test for Neuroleptic Sensitivity and Extrapyramidal Symptoms. J Clin Psychiatry 2004;65(suppl 11):16- 22
530. Shibao CA, Kaufmann H. Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease. CNS Drugs. 2017 Nov; 31(11):975-989
531. Taylor J.P, McKeith I.G. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2): с.157-169
532. Comella CL, Nardine TM, Diederich NJ, Stebbins G.T. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998 Aug; 51(2):526-9.
533. Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Ramar K, Kristo DA, Morgenthaler TI, Standards of Practice Committee., American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010 Feb 15; 6(1):85-95.
534. Schenck CH, Montplaisir JY, Frauscher B et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013 Aug; 14(8):795-806.
535. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003 Nov 25; 61(10):1418-20.